Science Market Update

UCLA Receives $1M Donation for Lung Disease Treatments

Posted by Laura Braden on Mon, Jan 25, 2016

UCLA has received $1 million dollars to support research into lung disease and organ rejection. When vital organs in the body, such as the lungs, begin to fail, an organ transplant can be a solution to the problem. However, receiving a transplant may have its own complications, such as the body rejecting its new organ.

Now, thanks to a generous donation of $1 million dollars from Michael and Linda Keston, researchers from the Division of Pulmonary and Critical Care Medicine at the UCLA David Geffen School of Medicine will be able to continue studying lung disease and the organ rejection commonly following a transplant. 

Steven Dubinett, M.D., from the University of California, Los Angeles Division of Pulmonary and Critical Care Medicine explained, "It is the vision of philanthropists like Linda and Michael that lays the groundwork for breakthroughs. This important donation will create new opportunities for discoveries that meet the challenges involved in advanced lung disease and transplantation.”

Over the next five years, this donation will support life scientists who are researching the rejection of transplanted organs and the molecular mechanisms involved in this process. Chemokines, signaling proteins, will be one of the primary research areas in this study. Chemokines send signals instructing cells to fight "foreign" objects in the body, such as new organs. In order for a transplanted organ to thrive in the body, the natural immune response to attack foreign objects must be suppressed. A deeper understanding of the proteins involved in organ rejection will ultimately help transplant patients live longer and healthier lives. 

“The Kestons’ contribution will enable our faculty to pursue innovative research that will eventually lead to new treatments to the benefit of countless patients,” explained Dr. John Mazziotta, Vice Chancellor of UCLA Health Sciences.

In November 2015, UCLA began a new initiative called the UCLA Lung Health Research Initiative, which the Kestons' donation will support. This initiative is part of a larger campaign, the UCLA Centennial Campaign, that is striving to raise $4.2 billion in funding for the university by 2019.  

Researchers at a past Biotechnology Vendor Showcase™ Event in Los Angeles learn about the best and newest tools and technologies available to use in their labs.

The University of California, Los Angeles receives millions of dollars annually from public and private donors to support life science research initiatives. In 2014, UCLA ranked 9th in the nation for total life science R&D expenditures, spending over $674.2 million. In the 2015 fiscal year, UCLA researchers received more than $371.3 million in funding from the National Institutes of Health (NIH) alone.


UCSF Granted $20M for HIV Research Institute

Athens Scientists Granted $2.1M for Vitamin Research

Network with 1000+ California Life Scientists

Departments at UCLA receiving substantial amounts of this funding include:

  • Internal Medicine/Medicine - $102.8 million

  • Neurology - $18.05 million

  • Physiology - $16.8 million

  • Biochemistry - $16.6 million

  • Radiation-Diagnostic/Oncology - $13.5 million

Biotechnology Calendar, Inc. hosts two Biotechnology Vendor Showcase™ Events at UCLA each year, providing laboratory suppliers with the opportunity to market their products to active life science researchers in Los Angeles. Between both events in 2015, over 1,100 researchers from 39 different research buildings and 66 on-campus departments at UCLA attended.

2016 events are scheduled for:

April 28th, 2016 – 37th Semiannual Biotechnology Vendor Showcase Event

October 20th, 2016 – 38th Semiannual Biotechnology Vendor Showcase™ Event

To learn more about participating in these popular events, visit the following link:

Exhibitors:  UCLA Event



Tags: CA, University of California Los Angeles, Los Angeles, LAVS, UCLA, Biotechnology Vendor Showcase, new funding, 2016, Lung Disease, organ transplant, organ rejection

Subscribe to Company News